###begin article-title 0
###xml 93 96 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Characterization of a Peptide Domain within the GB Virus C NS5A Phosphoprotein that Inhibits HIV Replication
###end article-title 0
###begin p 1
Conceived and designed the experiments: JS JX JM. Performed the experiments: JX JM QC EJ. Analyzed the data: JS JX JM QC EJ. Contributed reagents/materials/analysis tools: JS JM. Wrote the paper: JS JX JM QC EJ.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 70 76 <span type="species:ncbi:9606">people</span>
###xml 81 86 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 96 99 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 154 159 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 231 234 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 296 299 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GBV-C infection is associated with prolonged survival in HIV-infected people and GBV-C inhibits HIV replication in co-infection models. Expression of the GBV-C nonstructural phosphoprotein 5A (NS5A) decreases surface levels of the HIV co-receptor CXCR4, induces the release of SDF-1 and inhibits HIV replication in Jurkat CD4+ T cell lines.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 81 84 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 127 130 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 361 364 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 471 474 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 506 509 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 583 586 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 805 808 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 831 834 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Jurkat cell lines stably expressing NS5A protein and peptides were generated and HIV replication in these cell lines assessed. HIV replication was significantly inhibited in all cell lines expressing NS5A amino acids 152-165. Substitution of an either alanine or glycine for the serine at position 158 (S158A or S158G) resulted in a significant decrease in the HIV inhibitory effect. In contrast, substituting a phosphomimetic amino acid (glutamic acid; S158E) inhibited HIV as well as the parent peptide. HIV inhibition was associated with lower levels of surface expression of the HIV co-receptor CXCR4 and increased release of the CXCR4 ligand, SDF-1 compared to control cells. Incubation of CD4+ T cell lines with synthetic peptides containing amino acids 152-167 or the S158E mutant peptide prior to HIV infection resulted in HIV replication inhibition compared to control peptides.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 87 95 87 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 367 375 367 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 14 19 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 71 74 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 340 343 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 401 406 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Expression of GBV-C NS5A amino acids 152-165 are sufficient to inhibit HIV replication in vitro, and the serine at position 158 appears important for this effect through either phosphorylation or structural changes in this peptide. The addition of synthetic peptides containing 152-167 or the S158E substitution to Jurkat cells resulted in HIV replication inhibition in vitro. These data suggest that GBV-C peptides or a peptide mimetic may offer a novel, cellular-based approach to antiretroviral therapy.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 412 415 412 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Sulkowski1">[1]</xref>
###xml 543 546 543 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Antman1">[2]</xref>
###xml 690 693 690 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Stapleton1">[3]</xref>
###xml 698 701 698 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Zhang1">[4]</xref>
###xml 982 985 982 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Ensoli1">[5]</xref>
###xml 1135 1138 1127 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Barton1">[6]</xref>
###xml 1189 1197 1181 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1214 1217 1206 1209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Grivel1">[7]</xref>
###xml 1225 1228 1217 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Lisco1">[8]</xref>
###xml 1236 1239 1228 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang1">[9]</xref>
###xml 1240 1244 1232 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung1">[11]</xref>
###xml 1260 1264 1252 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Grivel2">[12]</xref>
###xml 1266 1270 1258 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Garcia1">[13]</xref>
###xml 1290 1294 1282 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Vanpouille1">[14]</xref>
###xml 1467 1471 1459 1463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 48 51 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 65 71 <span type="species:ncbi:9606">humans</span>
###xml 86 89 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 237 240 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 311 314 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 351 368 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 370 373 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 488 494 <span type="species:ncbi:9606">people</span>
###xml 604 609 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 652 655 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 779 782 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 937 940 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1173 1176 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1208 1213 <span type="species:ncbi:10368?0.8761061946902655">HHV-6</span>
###xml 1219 1224 <span type="species:ncbi:10372?0.8860759493670886">HHV-7</span>
###xml 1230 1235 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1246 1259 <span type="species:ncbi:11234">measles virus</span>
###xml 1330 1333 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1374 1377 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1432 1435 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Unlike most in vitro systems developed to study HIV replication, humans infected with HIV are co-infected with a variety of pathogenic and nonpathogenic microbes. These coinfections may have unilateral or bidirectional interactions with HIV that may alter the clinical outcome of either infection. For example, HIV infection accelerates the course of hepatitis C virus (HCV) related hepatic disease (reviewed in [1]), and is associated with an increased prevalence of Kaposi's sarcoma in people with coexistent herpesvirus 8 (HHV-8) infection [2]. In contrast, persistent infection with GB virus type C (GBV-C) is associated with prolonged survival in HIV-infected individuals (reviewed in [3] and [4]). Identification of the mechanism(s) by which microbial coinfections inhibit HIV replication may identify novel therapeutic targets or assist in the development of prevention strategies. Microbial interactions may be direct, (e.g. the HIV tat protein stimulates HHV-8 replication)[5] or indirect (gammaHV68 stimulates prolonged production of the IFNgamma, upregulating the basal state of innate immunity against subsequent infection)[6]. Several viral infections inhibit HIV replication in vitro including HHV-6 [7], HHV-7 [8], GBV-C [9]-[11], measles virus [12], [13], and vaccina virus [14]. Several of these infections alter HIV replication by decreasing expression of HIV coreceptors and inducing chemokines that compete with HIV for binding to entry receptors [10].
###end p 9
###begin p 10
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Stapleton2">[15]</xref>
###xml 380 383 380 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Sulkowski1">[1]</xref>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Linnen1">[16]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Simons1">[17]</xref>
###xml 546 550 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Dawson1">[18]</xref>
###xml 551 555 551 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Klinzman1">[22]</xref>
###xml 694 698 694 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Stapleton2">[15]</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Stapleton2">[15]</xref>
###xml 1039 1043 1039 1043 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Alter1">[23]</xref>
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 66 72 <span type="species:ncbi:9606">humans</span>
###xml 351 356 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 557 562 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 734 737 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 764 767 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 857 862 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1025 1030 <span type="species:ncbi:9606">human</span>
GBV-C is a common lymphotropic virus that may persist in infected humans for decades, although the majority of immune competent individuals clear viremia within two years of infection (reviewed in [15]). Antibody to the envelope glycoprotein E2 is usually detected following clearance of viremia, and detection of this antibody is indicative of prior GBV-C infection (reviewed in [1]). Viremia is present in approximately 2% of healthy blood donors in the United States [16], [17] and E2 antibodies are found in another 9% to 12% of these donors [18]-[22]. GBV-C prevalence is higher in developing countries and in U.S. populations that have other blood-born or sexually transmitted infections [15]. For example, approximately 20% of HCV-infected and up to 42% of HIV-infected individuals are viremic in cross-sectional studies (reviewed in [15]). Although GBV-C was initially thought to cause hepatitis, thorough investigation has failed to conclusively identify an association between the virus and hepatitis, or any other human disease [23].
###end p 10
###begin p 11
###xml 105 117 105 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Flaviviridae</italic>
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Linnen1">[16]</xref>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Simons1">[17]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Fogeda1">[24]</xref>
###xml 260 264 260 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Madejon1">[28]</xref>
###xml 351 354 351 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang1">[9]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung1">[11]</xref>
###xml 361 365 361 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang4">[29]</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung2">[30]</xref>
###xml 569 573 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 575 579 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung1">[11]</xref>
###xml 581 585 574 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang4">[29]</xref>
###xml 587 591 580 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung2">[30]</xref>
###xml 819 823 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 825 829 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung1">[11]</xref>
###xml 71 76 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 153 158 <span type="species:ncbi:9606">human</span>
###xml 296 301 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 306 309 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 335 338 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 373 376 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 433 436 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 607 612 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 691 694 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 734 737 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
On the basis of nucleotide sequence and predicted genome organization, GBV-C is classified in the family Flaviviridae[16], [17]. The virus replicates in human peripheral blood mononuclear cells (PBMCs) including B and T lymphocytes (CD4+ and CD8+ subsets)[24]-[28] and co-infection of PBMCs with GBV-C and HIV results in inhibition of HIV replication [9]-[11], [29], [30]. HIV inhibition is mediated in part by downregulation of the HIV co-receptors CCR5 and CXCR4 and by the induction of the ligands for these chemokine receptors (RANTES, MIP-1alpha, MIP-1beta, SDF-1)[10], [11], [29], [30]. Consequently, GBV-C co-infection of PBMCs inhibits the replication of both CCR5- and CXCR4-tropic HIV isolates (R5 and X4 respectively), and HIV isolates representing clades A through H and the more divergent group O isolates [10], [11].
###end p 11
###begin p 12
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Leary1">[31]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Khudyakov1">[32]</xref>
###xml 383 391 383 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 391 395 391 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung2">[30]</xref>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung2">[30]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Polgreen1">[34]</xref>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Jung2">[30]</xref>
###xml 919 923 919 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 1060 1064 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 1066 1070 1066 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Chang1">[35]</xref>
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 116 121 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 325 330 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 367 370 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 481 484 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 521 526 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 599 602 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 814 819 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 903 906 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 925 930 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1115 1120 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1159 1162 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GBV-C has a single strand, positive sense RNA genome encoding a polyprotein of approximately 3000 amino acids [31]. GBV-C structural proteins reside at the amino terminal one third of the polyprotein and are processed by cellular signal peptidases, while the nonstructural proteins are processed by viral proteases [32]. Two GBV-C proteins have been shown to inhibit HIV replication in vitro[30], [33]. Addition of the envelope glycoprotein (E2) to CD4+ T cells inhibits R5 and X4 HIV isolates [30], [34]. Infection with GBV-C and exposure of cells to E2 protein decreased surface expression of the HIV entry coreceptor CCR5, and also induced RANTES, one of the three known ligands for CCR5. The mechanism by which E2 inhibits X4 viruses has not been fully characterized [30]. In addition to E2, expression of the GBV-C nonstructural phosphoprotein NS5A in a CD4+ T cell line (Jurkat) potently inhibits HIV replication [33]. GBV-C NS5A decreases surface expression of CXCR4, and increases the release of SDF-1 (the CXCR4 ligand) into cell culture supernatants [33], [35]. In this study, we further characterize the GBV-C NS5A peptide requirements involved in HIV inhibition by mutagenesis, and determined that synthetic peptides are able to reproduce the effects of the intracellularly expressed NS5A peptides.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 24 29 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Characterization of the GBV-C NS5A domain required for HIV inhibition
###end title 14
###begin p 15
###xml 153 157 153 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 475 479 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 481 485 481 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Chang1">[35]</xref>
###xml 903 909 903 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g001">Fig. 1</xref>
###xml 1324 1328 1324 1328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 1600 1606 1600 1606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g002">Fig. 2</xref>
###xml 1909 1915 1909 1915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g002">Fig. 2</xref>
###xml 2080 2084 2080 2084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 60 65 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 137 140 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 219 224 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 308 311 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 376 379 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 578 581 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1001 1004 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1056 1061 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1330 1333 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1397 1402 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1473 1476 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1651 1656 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1726 1729 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1816 1821 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1904 1907 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1973 1978 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 2027 2030 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2155 2160 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 2249 2252 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2270 2273 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Previous studies demonstrated that stable expression of the GBV-C NS5A protein in a CD4+ T lymphocyte cell line (Jurkat cells) inhibited HIV replication [33]. The effect required protein expression, as cells expressing GBV-C NS5A RNA in which a frame-shift mutation that did not express NS5A did not inhibit HIV [33]. Based on the expression of peptide deletions of NS5A, the HIV inhibitory effect was mapped by sequential deletion mutational analysis to amino acids 152-181 [33], [35]. To further characterize the region within this 30 amino acid NS5A sequence responsible for HIV inhibition, Jurkat cell lines were generated that stably expressed a number of NS5A peptides, including some designed to mutate a specific amino acid. Representative NS5A fragments previously described and seven new NS5A constructs were used to generate stably expressing Jurkat cell lines in this study as summarized in Fig. 1. The NS5A sequences were inserted into a bicistronic vector that utilizes a tet-responsive CMV promoter to drive transcription, and for which the GBV-C NS5A sequences were expressed as the upstream open reading frame (ORF) followed by stop codons, and an encephalomyocarditis internal ribosomal entry site that directs translation of green fluorescent protein (GFP) from the downstream ORF as previously described [33]. HIV replication was significantly reduced in cell lines expressing GBV-C NS5A amino acids 1-181, 152-181, 152-167 and 152-165 when compared to HIV replication in three cell lines containing the NS5A frame-shift RNA and cells expressing NS5A amino acids 1-109 and 1-151 (Fig. 2). Thus all Jurkat cell lines that expressed GBV-C NS5A peptides containing amino acids 152-165 significantly inhibited HIV replication compared to the vector and frame-shift controls. Cell lines that included GBV-C NS5A coding regions that did not include NS5A amino acids 152-165 did not inhibit HIV (Fig. 2 and data not shown). Addition of doxycycline to decrease GBV-C NS5A peptide expression decreased the extent of HIV replication consistent with previous experiments [33](data not shown). Thus expression of a 14 amino acid region within the GBV-C NS5A protein (152-165) in this CD4+ T cell line was sufficient to significantly inhibit HIV replication. All HIV infections were performed in triplicate and repeated at least twice with consistent results.
###end p 15
###begin title 16
###xml 11 16 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Summary of GBV-C NS5A proteins stably expressed in Jurkat - Tet-off cells.
###end title 16
###begin p 17
###xml 41 46 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 179 184 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 484 487 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 604 607 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Boxes represent the amino acid region of GBV-C NS5A expressed in cloned Jurkat cell lines. Full length NS5A is 414 amino acids in length (1-414). The 126 frame-shift-237 contains GBV-C NS5A sequences that normally encodes these amino acids in the NS5A protein; however, a plus 1 frame shift was introduced so that the cells encode 26 missense amino acids. The amino acid sequence is shown for the 16mer peptide (152-167) and mutant peptides. Shaded boxes indicate cell lines in which HIV replication was inhibited compared to vector controls. Boxes with cross-hatches represent cell lines that inhibited HIV replication compared to controls, but significantly less than those cells indicated by solid shading. * = cell lines described previously.
###end p 17
###begin title 18
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 72 77 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
HIV growth characteristics in selected Jurkat cell lines expressing the GBV-C NS5A sequences.
###end title 18
###begin p 19
###xml 92 98 92 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g001">Fig. 1</xref>
###xml 221 228 221 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 58 63 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 126 129 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 310 313 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 352 355 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV replication in selected cell lines expressing various GBV-C NS5A peptides summarized in Fig. 1 was assessed by monitoring HIV p24 antigen release into culture supernatants. FS = the 126-237 frame-shift construct (see methods). Numbers refer to the NS5A amino acid sequence expressed in each cell line. * = HIV replication curves significantly less HIV p24 antigen than the frame shift control. (P<0.01 for the three cell lines that included amino acids 152-165 on days 3, 4, 5).
###end p 19
###begin p 20
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 191 195 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang6">[36]</xref>
###xml 597 601 597 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Maciejewski1">[37]</xref>
###xml 796 802 796 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g001">Fig. 1</xref>
###xml 894 901 894 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3A</xref>
###xml 1180 1184 1180 1184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Yu1">[38]</xref>
###xml 1186 1193 1186 1193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3B</xref>
###xml 1338 1342 1338 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang6">[36]</xref>
###xml 4 9 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 366 369 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The GBV-C NS5A protein is predicted to be a phosphoprotein, and expression of NS5A in cells results in two immunoreactive proteins consistent with a basal and hyperphosphorylated state [33], [36]. The 152-167 NS5A peptide contains a serine residue at position 158 that is predicted to be phosphorylated (). To assess whether this serine residue is important for the HIV inhibitory effect, cell lines were generated that expressed the NS5A 16mer 152-167 (VDGIPVSWDADARAPA) or mutated NS5A 16mer peptides with nonconservative substitutions (S158A and S158G) or a phosphomimetic substitution (S158E) [37]. A negative control cell line was also generated that expressed the 152-167 amino acid sequence in a scrambled order (DVIRAGPAWDSVAPAD) that is not predicted to be phosphorylated (summarized in Fig. 1). Clonal cell lines for each construct were selected that expressed the GFP reporter gene (Fig. 3A). The relative expression of GFP varied between cell lines, consistent with previous studies showing that the larger the protein encoded in the upstream open reading frame in a bicistronic vector, the lower the expression of the IRES-driven downstream protein, in this case GFP [38]. Fig. 3B demonstrates that the full-length NS5A, which had the lowest level of GFP expression, expressed two immunoreactive proteins as shown previously [36].
###end p 20
###begin title 21
###xml 23 28 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Mutational analysis of GBV-C 152-167 NS5A peptide.
###end title 21
###begin p 22
###xml 710 713 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 996 999 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1080 1083 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Clonal cell lines stably transfected with NS5A peptides were selected by hygromycin resistance and examined for GFP expression (A). Cells expressed the full length NS5A protein (amino acids 1-414), an NS5A 16 amino acid protein (152-167), the same 16 amino acids scrambled (152-167scr), or peptides in which the serine (position 158) was replaced with alanine (S158A), glycine (S158G) or glutamic acid (S158E). VC = vector control cells and FS = frame-shift control cells. Background represents the background fluorescence of parental Jurkat cells. Panel B demonstrates two immunoreactive NS5A proteins in cells expressing 1-414 (5A) but not in the vector control (VC) cells. Actin loading controls are shown. HIV replication was significantly decreased in Jurkat cell lines expressing full-length NS5A (1-414), the 152-167 peptide, and the S158E mutant (*) compared to all other cell lines on days 5, 6, and 7 days post-infection (panel C). The S158A and S158G cell lines had significantly less HIV replication than FS and VC (dagger; P = 0.041 on day 7), but significantly more HIV replication than the 1-414, 152-167, and S158E cells (dagger; P<0.02 for all, day 7).
###end p 22
###begin p 23
###xml 39 46 39 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3B</xref>
###xml 447 451 447 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 488 497 488 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">figure 3A</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 596 600 596 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Chang1">[35]</xref>
###xml 278 281 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 376 381 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 846 849 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1005 1010 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Because the anti-NS5A antibody used in Fig. 3B does not detect the 16 amino acid NS5A peptides, additional testing was performed on cell lines containing the short peptide sequences. First, cellular DNA from the Jurkat cell lines was amplified using PCR primers upstream of the CMV promoter region and in the downstream GFP coding region, and the product including the entire GBV-C NS5A peptide coding region was sequenced as previously described [33]. For all of the cell lines shown in figure 3A, the NS5A peptide sequence was shown to be intact and linked to both IRES and GFP sequences [33], [35](data not shown). Secondly, total cellular RNA from the cells containing the NS5A peptides was extracted from each cell line, amplified by RT-PCR and the amplified products sequenced. All of these cell lines contained the NS5A mRNA linked to the CMV promoter and the downstream GFP sequences. No sequences were amplified when reverse transcriptase was not included in the buffer, thus confirming that the GBV-C peptide RNA sequences were transcribed in these cells (data not shown).
###end p 23
###begin p 24
###xml 168 175 168 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3C</xref>
###xml 519 526 519 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3C</xref>
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 287 290 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 648 651 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
HIV replication was significantly inhibited in the cell lines expressing the S158E peptide compared to vector control, frame-shift control, S158A and S158G cell lines (Fig. 3C; p<0.01 for all; T-test on days 5, 6, and 7). Jurkat cells expressing S158A and S158G mutations also inhibited HIV replication compared to the vector, frame-shift, and 152-167 scrambled peptide controls (p = 0.037 day 6 and p = 0.043 day 7), but this inhibition was significantly less than that observed in cells expressing the S158E peptide (Fig. 3C; p = 0.014 day 6, p = 0.001 day 7). Thus although the serine residue at position 158 appears to be important for maximal HIV inhibition, mutation to nonconservative amino acids did not completely abrogate the inhibitory effect.
###end p 24
###begin p 25
###xml 213 222 213 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g004">Figure 4A</xref>
###xml 825 832 825 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g004">Fig. 4B</xref>
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 240 243 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 342 347 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 401 404 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 596 599 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 697 700 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 733 736 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To ensure that these results were not the result of cellular abnormalities introduced during clonal selection, HIV replication in the bulk cell lines that were used to generate the clonal cell lines was analyzed. Figure 4A illustrates that HIV replication was significantly inhibited in these cell lines, and confirmed that expression of the GBV-C NS5A 152-167 peptide and the S158E peptide inhibited HIV significantly more than the vector control, scrambled peptide, and both S158G and S158A peptides (p<0.001 days 3 through 6). However, the S158G and S158A peptides were again shown to inhibit HIV replication when compared to the vector and scrambled peptide control cell lines. The pattern of HIV inhibition was not altered when HIV infection was allowed to proceed longer in the clonal Jurkat cell lines (up to 20 days; Fig. 4B).
###end p 25
###begin title 26
###xml 14 19 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Expression of GBV-C NS5A peptides and HIV replication.
###end title 26
###begin p 27
###xml 15 18 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 111 114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 182 187 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 369 372 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 511 516 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 552 557 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
To ensure that HIV inhibition was not due to abnormalities selected for during clonal selection of cell lines, HIV replication was assessed in the bulk cell lines that expressed the GBV-C NS5A 152-167 peptide, the scrambled peptide (152-167Scr), and the mutated peptides (S158A, S158G, S158E) and compared to the vector control cell line (VC) (panel A). The pattern of HIV inhibition did not change appreciably when infections were followed for up to 20 days (panel B). 1-414 = cells expressing the full-length GBV-C NS5A and FS = cells expressing the GBV-C NS5A frame shift control.
###end p 27
###begin p 28
###xml 30 34 30 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
Consistent with prior studies [33], expression of full-length and NS5A peptides did not have any morphologic effects on Jurkat cells nor did they alter viability. Specifically, cell number increased equally between vector control and NS5A-expressing cell lines after five days in culture, and >98% of cells were viable by MTT and trypan blue exclusion analyses for all cell lines (data not shown).
###end p 28
###begin p 29
###xml 522 529 522 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g005">Fig. 5A</xref>
###xml 719 726 719 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g004">Fig. 4A</xref>
###xml 1211 1220 1211 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g005">Figure 5B</xref>
###xml 16 21 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 130 135 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 254 265 <span type="species:ncbi:11161">mumps virus</span>
###xml 619 624 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 666 671 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 694 705 <span type="species:ncbi:11161">mumps virus</span>
###xml 735 740 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 785 788 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 938 941 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 972 975 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1120 1123 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1391 1394 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To determine if GBV-C NS5A expression was specific for HIV replication inhibition, Jurkat cells stably expressing the full-length GBV-C NS5A (1-414), the 152-181 NS5A peptide, vector control (expressing GFP), and parental Jurkat cells were infected with mumps virus (MOI = 1.0; Jeryl-Lynn [vaccine] strain). The infectious titer of mumps in culture supernatants four days post-infection in Vero cells demonstrated that mumps replicated equally well in the parent, vector control, and the NS5A (152-181) Jurkat cell lines (Fig. 5A). Interestingly, the mumps titer was reproducibly higher in cells expressing full-length GBV-C NS5A (1-414)(p = 0.029), indicating that GBV-C NS5A somehow enhanced mumps virus replication (Fig. 4A). Since GBV-C NS5A 152-181 and 1-414 expression inhibited HIV replication, the enhancement in mumps replication appears to be mediated by a different region within NS5A. To further assess the specificity of the HIV inhibition, VSV-G pseudotyped HIV particles containing a luciferase reporter gene were prepared and assessed for their ability to transduce the various cell lines. Non-enveloped HIV particles containing the luciferase reporter served as the negative control particles. Figure 5B demonstrates that VSV-G transduction efficiency was not statistically different in any of the NS5A expressing cells compared to the vector control, irrespective of their HIV inhibitory phenotype.
###end p 29
###begin title 30
###xml 57 60 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The inhibitory effect of NS5A expression is specific for HIV replication.
###end title 30
###begin p 31
###xml 24 35 <span type="species:ncbi:11161">mumps virus</span>
###xml 93 98 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 204 215 <span type="species:ncbi:11161">Mumps virus</span>
The infectious titer of mumps virus was not inhibited in Jurkat cells expressing full-length GBV-C NS5A (1-414) or the 152-181 NS5A peptide compared to the vector control (VC) or parent Jurkat cells (A). Mumps virus replication was increased in Jurkat cells expressing full-length NS5A (*; p = 0.029). Similarly, panel B demonstrates that VSV-G pseudotyped retroviruses transduced all NS5A and control cell lines with similar efficiency as measured by relative luciferase activity in VSV-G pseudotype particles relative to the no-envelope control particles (p>0.05 for all compared to VC). 152-167 = cells expressing this NS5A 16mer peptide, Scr = cells expressing scrambled 16mer peptide, and S-A, S-G, S-E = cells expressing the S158A, S158G, and S158E substitutions.
###end p 31
###begin title 32
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
GBV-C NS5A peptide expression and chemokine receptors
###end title 32
###begin p 33
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 477 483 477 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g006">Fig. 6</xref>
###xml 14 19 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 179 184 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 229 232 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 304 309 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 333 336 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Expression of GBV-C NS5A in Jurkat cells was previously shown to downregulate CXCR4 surface expression [33]. Jurkat cell lines were examined by flow cytometry to determine if the GBV-C NS5A peptides altered surface expression of HIV co-receptors CXCR4 and CCR5. CXCR4 was reduced on cells expressing the GBV-C NS5A peptides in which HIV replication was most potently inhibited, but not in control cell lines or in cell lines expressing the S158A, S158G, or scrambled peptides (Fig. 6). CCR5 was not detected on any of the Jurkat cell lines including the parent cell line (data not shown).
###end p 33
###begin title 34
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
GBV-C NS5A peptides downregulate CXCR4 expression.
###end title 34
###begin p 35
Cells expressing the full-length NS5A (1-414), the 152-167 and S158E peptide had significantly less CXCR4 on their surface than did cells containing the vector control (VC), frameshift (FS), scrambled 152-167 peptide sequence (Scr), or the S158G, and S158A peptides. Data represent the mean fluorescent intensity of CXCR4 on the surface of these cells measured by flow cytometry.
###end p 35
###begin p 36
###xml 191 198 191 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g007">fig. 7A</xref>
###xml 556 563 556 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g007">Fig. 7B</xref>
###xml 1032 1039 1032 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g007">Fig. 7A</xref>
###xml 1291 1295 1289 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 137 142 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 982 985 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1146 1149 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1254 1257 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1374 1377 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1508 1511 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
SDF-1 release into culture supernatants was induced in cells in which CXCR4 expression was diminished, including cell lines that express GBV-C NS5A amino acids 152-165, 152-167, and 152-181 (fig. 7A) compared to the vector and frame-shift controls (p<0.01 for all three). Consistent with these findings, cells expressing the full-length NS5A (1-414), 152-167 and the S158E phosphomimetic substitution induced SDF-1 release compared to the cells expressing the vector control, the scrambled peptide, S158A, and S158G peptides and the frame-shift sequences (Fig. 7B; p<0.02 for all). There was variability in the amount of SDF-1 released in different experiments; however, the pattern of induction was similar between experiments. Cell lines expressing the parental NS5A sequences including 152-165 released significantly more SDF-1 than the vector, frame-shift and scrambled peptide controls when maintained in culture. The S158A and S158G peptides did not induce SDF-1, even though HIV replication was reduced compared to controls (Fig. 7A). This provides additional evidence that SDF-1 induction is not the sole mechanism by which NS5A inhibits HIV replication in these cells. Previous studies demonstrated that addition of >/=350 pg/mL SDF-1 inhibited HIV replication in CD4+ cell culture [10], thus the amount of SDF-1 released into supernatants is sufficient to inhibit HIV replication. Of note, SDF-1 release did not increase until days 4 or 5, further indicating that this is not the sole mechanism of HIV inhibition. RANTES, MIP-1alpha and MIP-1beta were not detected in any of the culture supernatants (data not shown).
###end p 36
###begin title 37
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
GBV-C NS5A peptides increase the release of stromal cell-derived factor 1 (SDF-1).
###end title 37
###begin p 38
###xml 91 96 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
SDF-1 release into culture supernatants was significantly greater in cell lines expressing GBV-C NS5A peptides 152-165, 152-167 and 152-181 compared to the vector control (VC) or frame shift (FS) cell lines after 7 days in culture (* p<0.01 for all; panel A). Jurkat cells expressing full-length NS5A (1-414), the 152-167 peptide and the S158E mutant peptide also induced significantly more SDF-1 than did cells expressing VC, FS or the S158A and S158G peptides (B; * p<0.02 for all on day 7).
###end p 38
###begin title 39
###xml 10 15 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Synthetic GBV-C NS5A peptides inhibit HIV replication
###end title 39
###begin p 40
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 822 831 810 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g008">figure 8A</xref>
###xml 92 95 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 148 153 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 264 267 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 362 365 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 449 452 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 515 518 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 555 560 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 645 648 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 860 863 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Based on our initial data demonstrating that an 85 amino acid fragment within NS5A inhibits HIV replication [33], overlapping peptides representing GBV-C NS5A amino acids 152-191, 172 to 211, and 197 to 236 were synthesized and tested for their ability to inhibit HIV when added to CD4+ T cell lines. To test the peptides in a cell line that supports high level HIV replication, MT-2 cells were incubated with the three peptides for 24 hrs prior to HIV infection and peptides were maintained in the media following HIV infection. The peptide representing GBV-C NS5A amino acids 152-191, but not the other two NS5A overlapping peptides inhibited HIV replication compared to the no peptide control on the fifth day post-infection in a dose-dependent manner (37% at 10 microg/mL; 58% at 25 microg/mL and 71% at 50 microg/mL; figure 8A). Although the magnitude of HIV inhibition was less than that observed when the peptides were expressed within Jurkat cells, the inhibition was statistically significant (p<0.01 at 25 and 50 microg/ml).
###end p 40
###begin title 41
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 38 41 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GBV-C NS5A synthetic peptides inhibit HIV replication.
###end title 41
###begin p 42
###xml 45 50 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 109 112 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 166 169 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 291 296 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 377 380 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 414 417 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 560 563 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 579 582 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 610 613 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 698 701 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 719 722 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 758 761 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 815 818 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 919 922 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Addition of a synthetic peptide representing GBV-C NS5A amino acids 152-191 (P1) to MT-2 cells 1 hour before HIV infection resulted in a dose-dependent inhibition of HIV replication (concentration of peptide = 10, 25, or 50 microg/ml; panel A). By comparison, overlapping peptides including GBV-C NS5A amino acids 172 to 211 (P2) or amino acids 197 to 236 (P3) did not inhibit HIV replication at 50 microg/mL. All HIV replication was compared to cells incubated with no peptide (NP). Addition of peptide 1 (amino acids 152-191) to Jurkat cells 24 hrs prior to HIV infection [(1) HIV] resulted in inhibition of HIV on day 4 (dagger p<0.05; panel B). In cells in which peptide was not included after HIV infection (- P), HIV inhibition was lost on day 5. When HIV and the peptides were added to cells simultaneously (HIV+P), inhibition was not observed on day 4; however, when the peptide was included in the media (+P), HIV replication was inhibited by day 5 (* p<0.05 compared to the NP control).
###end p 42
###begin p 43
###xml 491 498 491 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g008">Fig. 8B</xref>
###xml 798 805 798 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g008">Fig. 8B</xref>
###xml 1260 1267 1260 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g008">Fig. 8B</xref>
###xml 218 221 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 250 253 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 275 278 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 387 390 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 531 534 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 643 646 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 961 964 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1018 1021 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1135 1138 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1181 1184 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1248 1251 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
To further assess if the timing that peptides were added to cells, or if the type of CD4+ T cell line influenced the inhibitory effect, Jurkat cells were incubated with the inhibitory peptide (152-191) 24 hrs prior to HIV infection or at the time of HIV infection. Following HIV infection, cells were washed and incubated either with or without the peptide. As expected the magnitude of HIV replication was significantly lower in the control Jurkat cells compared to the control MT-2 cells (Fig. 8B). However, a similar pattern of HIV inhibition by the 152-191 NS5A peptide was observed in cells incubated with the peptide for 24 hrs prior to HIV infection compared to controls. This inhibition persisted for the first 4 days post infection, whether or not the peptide was maintained in the media (Fig. 8B). However, the inhibitory effect was lost by day 5 in cells maintained in media without peptide. In contrast, addition of peptides to cells at the time of HIV infection did not lead to significant differences in HIV replication from controls during the first 4 days post-infection. Nevertheless, cells maintained in peptide post-HIV infection demonstrated significantly less HIV release on day 5, presumably due to inhibition of cell-to-cell HIV spread (Fig. 8B).
###end p 43
###begin p 44
###xml 52 61 52 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g001">Figures 1</xref>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">3</xref>
###xml 587 591 583 587 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Hermann1">[39]</xref>
###xml 803 816 799 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g009">Fig. 9A and B</xref>
###xml 918 925 914 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g009">Fig. 9C</xref>
###xml 1006 1012 1002 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3</xref>
###xml 1083 1090 1079 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g009">Fig. 9C</xref>
###xml 1160 1173 1156 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g009">Fig. 9A and B</xref>
###xml 1377 1380 1373 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang1">[9]</xref>
###xml 1382 1386 1378 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang3">[25]</xref>
###xml 1388 1392 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Wunschmann1">[40]</xref>
###xml 176 179 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 227 230 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 327 330 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 866 869 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1078 1081 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Based on the deletion mapping and mutagenesis data (Figures 1 and 3), the active NS5A peptide mutant (S158E) and a control (152-167scr) peptide were synthesized and tested for HIV inhibition when added to cells 24 hrs prior to HIV infection (concentration up to 50 microg/mL). Neither of these peptides significantly inhibited HIV replication (data not shown). To determine if this reflected poor uptake and/or degradation of the peptides, the S158E peptide and the scrambled 152-167 peptide were synthesized with an N-terminal Tat-protein-transduction domain to improve cellular uptake [39], and the peptides were conjugated to FITC to allow monitoring of cellular binding and uptake. Both the Tat-S158E and Tat-152-167-scrambled fusion peptides were taken up by MT-2 cells in a dose-dependent manner (Fig. 9A and B). Cells incubated in the S158E peptide inhibited HIV replication compared to the no peptide control (Fig. 9C), albeit to a lesser extent than expression of the peptide within Jurkat cells (Fig. 3). In contrast, the Tat-152-167scr fusion peptide did not inhibit HIV (Fig. 9C), even though it's cellular uptake was similar to the S158E peptide (Fig. 9A and B). No cellular toxicity or effect on viability was observed in MT-2 cells or Jurkat cells incubated in either of the peptides (50 ug/ml) as determined by cell counts, trypan blue exclusion, and MTT assay [9], [25], [40] (data not shown).
###end p 44
###begin title 45
###xml 29 32 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Dose dependent inhibition of HIV replication by the S158E mutant.
###end title 45
###begin p 46
###xml 112 117 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 378 381 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 438 441 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 564 567 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
MT-2 cells were incubated with three concentrations (10, 25, and 50 microg/ml) of synthetic peptides containing GBV-C S158E (A) or 152-167scr (B) amino acid sequences in which an N-terminal Tat-protein transduction domain was included, and the peptides were conjugated to FITC. Cells were washed one hour later and FITC was monitored by flow cytometry. Cells were infected with HIV 24 hrs after incubation, and dose related inhibition of HIV replication was observed for the S158E peptide, but not the 152-167scr peptide compared to the no peptide control (NP). * HIV p24 antigen area under the curve was less than controls (p<0.01).
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 103 111 103 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 261 267 261 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g001">Fig. 1</xref>
###xml 466 473 466 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3B</xref>
###xml 859 866 859 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">Fig. 3C</xref>
###xml 868 877 868 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g004">4A and 4B</xref>
###xml 1806 1810 1806 1810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Pan1">[41]</xref>
###xml 35 40 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 89 92 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 240 243 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 441 444 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 530 533 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 678 681 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 775 778 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 979 982 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1111 1114 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1131 1136 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1177 1180 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1190 1201 <span type="species:ncbi:11161">mumps virus</span>
###xml 1267 1270 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1338 1341 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1621 1624 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 1870 1881 <span type="species:ncbi:11161">mumps virus</span>
###xml 1909 1914 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1945 1950 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1983 1994 <span type="species:ncbi:11161">mumps virus</span>
###xml 2012 2015 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 2041 2046 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
The protein requirement within the GBV-C NS5A protein that is responsible for inhibiting HIV infection in vitro was further characterized in this study. Expression of ten different NS5A polypeptides containing amino acids 152-165 inhibited HIV in Jurkat cells (Fig. 1); however, scrambling the amino acid order of the 152-167 peptide abolished the inhibitory effect. Furthermore, the serine residue at position 158 appears important for the HIV inhibitory function (Fig. 3B), since a phosphomimetic substitution (S158E) inhibited HIV as well as the expression of either the full length NS5A protein or the parent peptide. Of note, the parent peptide and S158E peptide inhibited HIV significantly more than the S158A and S158G peptides; however, these peptides also inhibited HIV replication compared to the scrambled peptide, frame-shift and vector controls (Fig. 3C, 4A and 4B). These data are consistent with the hypothesis that the serine at position 158 is important for the HIV inhibitory effect of this peptide, and suggest that either phosphorylation or a structural motif of the peptide is required for HIV inhibition. The GBV-C NS5A inhibition effect was specific for HIV, as both mumps virus replication and the transduction efficiency of VSV-G pseudotyped HIV particles was not diminished in the NS5A expressing cells in which HIV replication was inhibited. Interestingly, full-length NS5A (1-414) enhanced mumps replication in Jurkat cells compared to parental and vector control cells. To our knowledge, viral enhancement has not been previously described for flavivirus NS5 proteins. However, expression of HCV NS5A in a HepG2 cell line was shown to enhance hepatitis B protein expression and virus replication, potentially as a result of NS5A partial inhibition of interferon responsiveness [41]. Ongoing studies are examining potential mechanisms of the mumps virus replication enhancement by GBV-C NS5A. Nevertheless, since the GBV-C 152-181 protein did not enhance mumps virus replication, the HIV inhibitory domain within GBV-C NS5A is distinct from the mumps-enhancing domain. This enhancement in mumps replication further emphasizes the data showing that NS5A expression is not toxic to the Jurkat cells.
###end p 48
###begin p 49
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Evans1">[42]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Macdonald1">[44]</xref>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 292 296 292 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang3">[25]</xref>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-George1">[26]</xref>
###xml 326 333 326 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 815 823 815 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 865 869 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang4">[29]</xref>
###xml 1060 1064 1060 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 9 14 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 90 93 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 374 379 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 445 450 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 454 457 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 512 517 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 562 565 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 708 713 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 782 787 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1038 1041 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1097 1100 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1141 1146 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Although GBV-C NS5A protein function is not completely understood; in the closely related HCV, NS5A is required for viral replication and is part of the viral replication complex [42]-[44]. NS5A expression is confined to actively infected cells, which comprise fewer than 5% of PBMCs in vitro[25], [26] and an unknown percent in vivo. Thus it is unlikely that the effect of GBV-C NS5A expression is directly responsible for all of the effect of GBV-C on HIV replication and disease progression. However, because GBV-C NS5A and the NS5A peptides downregulate the HIV co-receptor CXCR4 and induce the release of SDF-1, NS5A protein expression would appear to have a bystander effect on cells not infected with GBV-C. Consistent with these findings, previous studies demonstrated that GBV-C infection of healthy PBMCs in vitro resulted in the induction of SDF-1 [10], [29], and prior studies with full-length NS5A expressing Jurkat cells found that neutralizing SDF-1 activity with neutralizing antibodies diminished but did not abolish the HIV inhibitory effect [33]. Thus, additional mechanisms of HIV inhibition appear to be elicited by the GBV-C NS5A protein.
###end p 49
###begin p 50
###xml 281 287 281 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g002">Fig. 2</xref>
###xml 289 290 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g003">3</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g007">7</xref>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g008">8</xref>
###xml 45 50 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 153 156 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 440 443 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Addition of a synthetic peptide representing GBV-C NS5A 152-191 amino acids and the S158E mutant peptide to Jurkat and MT-2 cells reproducibly inhibited HIV replication, although to a less extent than that observed when the peptides were expressed intracellularly in Jurkat cells (Fig. 2, 3, 7, and 8). The S158E peptide was not active by itself; however, the addition of a tat-protein transduction domain to the amino terminus resulted in HIV inhibition for the S158E peptide but not the 152-167scr peptide. These data suggest, but do not prove that intracellular uptake of the native peptide and/or degradation may have contributed to it's lack of efficiency.
###end p 50
###begin p 51
###xml 425 432 425 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g004">Fig. 4B</xref>
###xml 303 306 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 714 719 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 819 822 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 824 836 <span type="species:ncbi:12637">Dengue virus</span>
###xml 838 856 <span type="species:ncbi:11089">yellow fever virus</span>
###xml 1028 1049 <span type="species:ncbi:328819|species:ncbi:379362|species:ncbi:219650|species:ncbi:329529|species:ncbi:133823|species:ncbi:261389|species:ncbi:184426|species:ncbi:261384|species:ncbi:302169">environmental samples</span>
The secondary structure of the 152-167 peptide and S158E mutant is predicted to contain a beta-strand (DNAMan software, Lynnon Biosoft). In contrast, the S158A, S158G, and 152-167scr peptides are not predicted to form a beta strands, suggesting that a critical peptidic structure is responsible for the HIV inhibitory interaction. The activity of the S158E peptide appeared to be potentially greater than the parent peptide (Fig. 4B). Comparison of the probability of the predicted structures indicates that the probability of a beta-strand is greater in the S158E peptide than the parent peptide, suggesting that this substitution may result in a more stable structure than the parent sequence. Alignments of the GBV-C NS5A 152-167 amino acid sequence with NS5 sequences of isolates representing related flaviviruses (HCV, Dengue virus, yellow fever virus, and West Nile Virus) did not identify >32% homology. In addition, Blast search () of all proteins (non-redundant GenBank CDS translations+PDB+SwissProt+PIR+PRF excluding environmental samples from WGS projects) did not identify proteins sharing homology with the 152-167 peptide or the S158E peptide.
###end p 51
###begin p 52
###xml 165 168 165 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Zhang1">[4]</xref>
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Bjorkman1">[45]</xref>
###xml 252 256 252 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Bjorkman2">[46]</xref>
###xml 258 262 258 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-VanderBij1">[47]</xref>
###xml 349 357 349 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 464 467 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Zhang1">[4]</xref>
###xml 578 582 578 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-George1">[26]</xref>
###xml 688 696 688 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g005">figure 5</xref>
###xml 698 699 698 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002580-g006">6</xref>
###xml 714 718 714 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 55 58 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 68 74 <span type="species:ncbi:9606">people</span>
###xml 195 200 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 220 223 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 316 319 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 409 414 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 439 442 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 474 477 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 479 484 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 533 538 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 837 840 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 940 945 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1061 1066 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1214 1217 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1304 1307 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GBV-C viremia is associated with prolonged survival in HIV-infected people in most studies conducted prior to the availability of combination antiretroviral therapy [4], although some argue that GBV-C is a marker of low HIV RNA [45] or high CD4 counts [46], [47]. Demonstration that NS5A peptide expression inhibits HIV replication adds to previous in vitro studies that support a causal relationship between GBV-C viremia and survival in HIV-infected individuals [4]. Like HIV, GBV-C replicates in CD4+ lymphocytes and in addition, GBV-C replicates in CD8+ T cells and B cells [26]. Since the NS5A 152-167 peptide induces the release of SDF-1 and downregulates CXCR4 surface expression (figure 5, 6 and reference [33]), it is reasonable to speculate that the bystander effect of NS5A expression and chemokine modulation would influence HIV replication in lymphoid tissue. Further studies to characterize the structural requirements of the GBV-C 152-167 NS5A peptide, and to identify intracellular interacting proteins are underway. These data suggest that the GBV-C NS5A peptide may be useful from a therapeutic standpoint. Because the peptide functions by altering CXCR4 and inducing SDF-1 instead of inhibiting HIV replicative enzymes, it may provide a therapeutic approach that is more difficult for HIV to overcome by the selection of virus mutations.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
###xml 0 5 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
GBV-C NS5A proteins and peptides
###end title 54
###begin p 55
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 704 708 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 1251 1255 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 16 21 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 144 149 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 291 317 <span type="species:ncbi:12104">encephalomyocarditis virus</span>
###xml 417 422 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 1438 1441 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The full length GBV-C NS5A protein coding sequence (numbering based on AF121950) was previously amplified from the plasma of an individual with GBV-C viremia, ligated into the pTRE2-Hyg plasmid (Clontech, Inc., Mountain View, CA) modified to include a stop codon after NS5A, followed by the encephalomyocarditis virus (EMC) IRES element directing the translation of green fluorescent protein (GFP) as described [33]. GBV-C NS5A deletion mutants were generated by using convenient restriction sites as previously described [33], and all of the peptide constructs were generated by ligating synthetic oligonucleotides containing flanking NheI and NotI restriction sites into the modified pTRE2-Hgy plasmid [33]. All sequences were confirmed by automated fluorescent dye terminator cycle sequencing (University of Iowa DNA Core Facility; Applied Biosystems automated DNA sequencer 373A, Foster City, CA). Tet-Off Jurkat cells (Clontech, Inc.) were transfected (Amaxa nucleofection, Amaxa Inc., Gaithersburg, MD) with plasmids containing NS5A sequences or with control sequences including the vector control expressing GFP, or with a vector that contains NS5A sequences with a single base insertion to create a frameshift mutation as previously described [33]. Following selection in hygromycin and neomycin (200 microg/ml each), bulk cell lines were examined for GFP expression. Cell lines stably expressing GFP were examined for support of HIV replication and CXCR4 surface expression, and clonal cell lines were prepared by at least two rounds of terminal dilution cloning.
###end p 55
###begin p 56
###xml 278 282 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang6">[36]</xref>
###xml 842 846 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang5">[33]</xref>
###xml 848 852 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Chang1">[35]</xref>
###xml 343 348 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 354 360 <span type="species:ncbi:9986">rabbit</span>
###xml 432 439 <span type="species:ncbi:28980">Redwood</span>
###xml 478 483 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 528 534 <span type="species:ncbi:110766|species:ncbi:562">E.coli</span>
To monitor NS5A expression, Jurkat cells were lysed in RIPA buffer containing protease and phosphatase inhibitors, clarified (13,000x g, 2 min at 4oC), and subjected to SDS-PAGE prior to transfer to nitrocellulose membranes (Bio Rad, Inc., Hercules, CA) as previously described [36]. Immunoreactive proteins were identified using the GE3 anti-GBV-C NS5A rabbit serum kindly provided by Dr. Jungsuh Kim (Genelabs Technologies, Inc., Redwood City, CA) which was generated against GBV-C nucleotide sequences 6615-6977 expressed in E.coli. For cell lines expressing NS5A fragments not detected by immunoblot, expression of GFP was demonstrated by flow cytometry and total cellular DNA and RNA was examined for linkage between NS5A sequences and GFP using PCR or RT-PCR followed by determination of the nucleotide sequence as previously described [33], [35]. DNA sequence alignments and predicted protein secondary structure analyses employed DNAMan software (Lynnen Biosoft, Inc., Pointe-Claire, Quebec, Canada).
###end p 56
###begin p 57
Synthetic peptides representing NS5A amino acid sequences were either kindly provided by Dr. Opendra Sharma and the NIH Aids Reference Reagent Program or purchased (New England Peptide LLC, Gardener MA or Iowa State University Protein Facility, Ames, IA).
###end p 57
###begin title 58
Virus infections
###end title 58
###begin p 59
###xml 265 266 265 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 298 302 298 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Wuenschmann1">[48]</xref>
###xml 650 653 650 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang1">[9]</xref>
###xml 655 659 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 3 8 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 180 185 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 243 246 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 314 317 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 448 453 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 467 472 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 513 516 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 570 575 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An HIV-1 isolate (X4, clade B; NIH AIDS Research and Reference Reagent Program, catalog number 1073) was used to infect CD4+ T cell lines (Jurkat cells and Jurkat cells expressing GBV-C NS5A peptides or control plasmids, or MT-2 cells; 200 pg HIV p24 antigen per 106 cells) as previously described [48]. Following HIV attachment, cells were washed, maintained in fresh media and culture supernatants were obtained at various time points to measure HIV-1 replication. HIV-1 replication was determined by measuring HIV p24 antigen in culture supernatant fluids (Retro-Tek HIV-1 p24 antigen ELISA kits, Zeptometrix, Buffalo, NY) as previously described [9], [10]. All infections were performed in triplicate and were independently repeated at least twice with consistent results.
###end p 59
###begin p 60
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Kenny1">[49]</xref>
###xml 11 22 <span type="species:ncbi:11161">mumps virus</span>
###xml 283 294 <span type="species:ncbi:11161">mumps virus</span>
###xml 375 380 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
Attenuated mumps virus (Jeryl-Lyn vaccine strain, Merck & Co., Whitehouse Station, NJ) was purchased and a stock virus preparation was generated to serve as a specificity control. The infectious titer of this preparation was determined in Vero cells as described by others [49]. The mumps virus preparation was used to infect Jurkat cells including cell lines that expressed GBV-C NS5A peptides or vector control cell lines.
###end p 60
###begin p 61
###xml 154 155 154 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 480 484 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Sinn1">[50]</xref>
###xml 633 637 625 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Sinn1">[50]</xref>
###xml 868 869 850 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 12 15 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 252 255 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 486 489 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 953 956 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 976 979 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Pseudotyped HIV particles were generated by transient transfection of plasmid DNA into 293T cells plated 2 days prior to transfection at a density of 1x106 per 10-cm-diameter culture dish. Two plasmid co-transfections were performed using 10 microg of HIV packaging construct (pNL4-3,Luc.R-E-; NIH AIDS Research and Reference Reagent Program catalog # 3417) and 10 microg VSV-G envelope-expressing plasmid (pHEF-VSVG; NIH AIDS Research and Reference Reagent Program catalog #4693)[50]. HIV particles without an envelope served as the control. DNA complexes were prepared with calcium chloride and transfected into cells as described [50], and medium was replaced 4 h after transfection. Culture supernatants were harvested 72 hours after the start of transfection, filtered through a 0.45 microm Nalgene filter, and stored at 4degreesC prior to use. Jurkat cells (8x104 cells/well) were placed into a 24-well plate and transduced with VSV-G pseudotyped HIV or the no-envelope HIV (gag) particles. Cells were lysed with Glo-Lysis buffer (Promega, Inc., Madison, WI) 72 hours after transduction and relative luciferase activity assessed as recommended by the manufacturer on a TD-20/20 Luminometer (Turner Biosystems, Sunnyvale, CA).
###end p 61
###begin title 62
Chemokines and chemokine receptors
###end title 62
###begin p 63
###xml 108 111 108 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang1">[9]</xref>
###xml 496 500 489 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002580-Xiang2">[10]</xref>
###xml 124 130 <span type="species:ncbi:9986">rabbit</span>
CXCR4 and CCR5 expression on the surface of cells were determined by flow cytometry as previously described [9]. Polyclonal rabbit anti-CCR5 (FITC-conjugated) and anti-CXCR4 (PE-conjugated) antibodies (BD Pharmingen, San Jose, CA) were used in these studies. Flow cytometry was performed using a FACScan (Becton Dickenson, San Jose, CA). SDF-1, RANTES, MIP-1alpha and MIP-1beta were detected in replicate culture supernatant fluids by ELISA (R&D Systems, Minneapolis, MN) as previously described [10].
###end p 63
###begin title 64
Statistics
###end title 64
###begin p 65
###xml 91 94 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 133 136 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 178 189 <span type="species:ncbi:11161">mumps virus</span>
Statistics were performed using SigmaStat software V3.11 (Jandel Scientific, Chicago, IL). HIV replication was analyzed by measuring HIV p24 antigen release or infectious titer (mumps virus) on various days post-infection, and comparisons were performed using T-tests.
###end p 65
###begin p 66
###xml 931 938 931 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">methods</xref>
###xml 336 339 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 879 882 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
We thank Donna Klinzman, Robert A Rydze, and Thomas Kaufman for technical assistance with these studies, Dr. Katherine Chaloner (University of Iowa College of Public Health) for assistance with statistical evaluation, and Drs. Paul McCray and Beverly Davidson (University of Iowa College of Medicine) for assistance in establishing the HIV pseudotype system. We thank Dr. Opendra Sharma (NIH AIDS Reference Reagent Program) for providing the 40mer peptides, Dr. Ramaswamy Subramanian (University of Iowa Protein Structure Facility) for helpful discussions, Dr. Jungsuh Kim (Genelabs, Inc.) for providing NS5A antiserum, and the Iowa State Protein Facility for peptide synthesis and purification. The University of Iowa Flow Cytometry and DNA Core Facilities were utilized for flow cytometry and DNA sequence analyses. We also thank the NIH AIDS Reference Reagent Program for the HIV isolate and plasmids used in these studies (see methods).
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
###xml 0 11 <span type="species:ncbi:11103">Hepatitis C</span>
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 32 38 <span type="species:ncbi:9606">Person</span>
Hepatitis C in the HIV-Infected Person.
###end article-title 68
###begin article-title 69
Kaposi's sarcoma.
###end article-title 69
###begin article-title 70
GB Virus C: A beneficial infection?
###end article-title 70
###begin article-title 71
###xml 25 30 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 54 57 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Effect of early and late GBV-C viremia on survival of HIV infected individuals: A meta-analysis.
###end article-title 71
###begin article-title 72
###xml 51 56 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.
###end article-title 72
###begin article-title 73
Herpesvirus latency confers symbiotic protection from bacterial infection.
###end article-title 73
###begin article-title 74
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 69 88 <span type="species:ncbi:10368">human herpesvirus 6</span>
Suppression of CCR5-but not CXCR4 tropic HIV-1 in lymphoid tissue by human herpesvirus 6.
###end article-title 74
###begin article-title 75
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 45 64 <span type="species:ncbi:10372">Human herpesvirus 7</span>
###xml 107 142 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Viral interactions in human lymphoid tissue: Human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation.
###end article-title 75
###begin article-title 76
###xml 39 56 <span type="species:ncbi:54290">Hepatitis G virus</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 90 93 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Effect of coinfection with GB Virus C (Hepatitis G virus) on survival among patients with HIV infection.
###end article-title 76
###begin article-title 77
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 35 45 <span type="species:ncbi:54290">GB virus C</span>
Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1.
###end article-title 77
###begin article-title 78
###xml 14 17 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Inhibition of HIV strains by GB Virus C in cell culture can be mediated by CD4 and CD8 T-lymphocyte derived soluble factors.
###end article-title 78
###begin article-title 79
###xml 14 19 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 69 82 <span type="species:ncbi:11234">measles virus</span>
Inhibition of HIV-1 replication in human lymphoid tissues ex vivo by measles virus.
###end article-title 79
###begin article-title 80
###xml 24 59 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 75 88 <span type="species:ncbi:11234">measles virus</span>
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.
###end article-title 80
###begin article-title 81
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 31 45 <span type="species:ncbi:10245">vaccinia virus</span>
###xml 49 54 <span type="species:ncbi:9606">human</span>
Interactions between HIV-1 and vaccinia virus in human lymphoid tissue ex vivo.
###end article-title 81
###begin article-title 82
###xml 16 33 <span type="species:ncbi:54290">Hepatitis G virus</span>
GB virus type C/Hepatitis G virus.
###end article-title 82
###begin article-title 83
###xml 45 62 <span type="species:ncbi:54290">hepatitis G virus</span>
Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent.
###end article-title 83
###begin article-title 84
###xml 56 61 <span type="species:ncbi:9606">human</span>
Isolation of novel virus-like sequences associated with human hepatitis.
###end article-title 84
###begin article-title 85
Prevalence Studies of GB Virus-C Infection Using Reverse Transcriptase-Polymerase Chain Reaction.
###end article-title 85
###begin article-title 86
###xml 18 28 <span type="species:ncbi:54290">GB virus C</span>
Expression of the GB virus C E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker.
###end article-title 86
###begin article-title 87
Detection of antibodies to a putative hepatitis g virus envelope protein.
###end article-title 87
###begin article-title 88
###xml 125 133 <span type="species:ncbi:9606">patients</span>
Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients.
###end article-title 88
###begin article-title 89
###xml 0 10 <span type="species:ncbi:54290">GB virus C</span>
###xml 11 28 <span type="species:ncbi:54290">hepatitis G virus</span>
GB virus C/hepatitis G virus: Does clearance of viremia differ based on mode of transmission?
###end article-title 89
###begin article-title 90
###xml 87 104 <span type="species:ncbi:54290">hepatitis G virus</span>
G-pers creepers, where'd you get those papers? A reassessment of the literature on the hepatitis G virus.
###end article-title 90
###begin article-title 91
###xml 22 27 <span type="species:ncbi:9606">human</span>
###xml 66 94 <span type="species:ncbi:54290">GB virus C/Hepatitis G virus</span>
In vitro infection of human peripheral blood mononuclear cells by GB virus C/Hepatitis G virus.
###end article-title 91
###begin article-title 92
Full-length GB Virus C (Hepatitis G Virus) RNA transcripts are infectious in primary CD4-Positive T cells.
###end article-title 92
###begin article-title 93
###xml 0 10 <span type="species:ncbi:54290">GB virus C</span>
GB virus C replicates in primary T and B lymphocytes.
###end article-title 93
###begin article-title 94
###xml 33 50 <span type="species:ncbi:54290">Hepatitis G virus</span>
Existence of distinct GB Virus C/Hepatitis G virus variants with different tropism.
###end article-title 94
###begin article-title 95
###xml 75 83 <span type="species:ncbi:9606">patients</span>
GB Virus C RNA in serum, liver and peripheral blood mononuclear cells from patients with chronic hepatitis B, C and D.
###end article-title 95
###begin article-title 96
###xml 14 24 <span type="species:ncbi:54290">GB virus C</span>
###xml 74 79 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 97 125 <span type="species:ncbi:12721">human immunodeficiency virus</span>
South African GB virus C isolates: Interactions between genotypes 1 and 5 GBV-C isolates and the human immunodeficiency virus.
###end article-title 96
###begin article-title 97
###xml 0 3 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 55 65 <span type="species:ncbi:54290">GB virus C</span>
HIV entry inhibition by the envelope 2 glycoprotein of GB virus C.
###end article-title 97
###begin article-title 98
###xml 37 42 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 95 100 <span type="species:ncbi:9606">human</span>
###xml 101 106 <span type="species:ncbi:12440">non-A</span>
Sequence and genomic organization of GBV-C: A novel member of the Flaviviridae associated with human non-A-E hepatitis.
###end article-title 98
###begin article-title 99
###xml 56 73 <span type="species:ncbi:54290">hepatitis G virus</span>
Sequence variation within a nonstructural region of the hepatitis G virus genome.
###end article-title 99
###begin article-title 100
###xml 77 82 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
An 85 amino acid segment of the GB Virus type C NS5A phosphoprotein inhibits HIV-1 replication in CD4+ Jurkat T-cells.
###end article-title 100
###begin article-title 101
###xml 16 33 <span type="species:ncbi:54290">Hepatitis G virus</span>
###xml 100 103 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
GB Virus type C/Hepatitis G virus: A nonpathogenic flavivirus associated with prolonged survival in HIV-infected individuals.
###end article-title 101
###begin article-title 102
###xml 107 112 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
GB Virus C NS5A protein from genotypes 1, 2, 3, and 5 and a 30 amino acid NS5A fragment expression inhibit HIV-1 replication in a CD4+ T-lymphocytes.
###end article-title 102
###begin article-title 103
GB Virus C NS5A sequence polymorphisms: Association with interferon susceptibility and inhibition of PKR-mediated eIF-2alpha phosphorylation.
###end article-title 103
###begin article-title 104
###xml 65 71 <span type="species:ncbi:9913">Bovine</span>
Mutation of Serine 90 to Glutamic Acid Mimics Phosphorylation of Bovine Prolactin.
###end article-title 104
###begin article-title 105
Quantification of target gene expression by imaging reporter gene expression in living animals.
###end article-title 105
###begin article-title 106
###xml 110 145 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Addition of a C-terminal cysteine improves the anti-herpes simplex virus activity of a peptide containing the human immunodeficiency virus type 1 TAT protein transduction domain.
###end article-title 106
###begin article-title 107
###xml 20 37 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 39 42 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 48 51 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low density lipoprotein receptor.
###end article-title 107
###begin article-title 108
###xml 16 19 <span type="species:ncbi:11103?0.9633797444211329">HCV</span>
###xml 29 32 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
NS5A protein of HCV enhances HBV replication and resistance to interferon response.
###end article-title 108
###begin article-title 109
###xml 19 36 <span type="species:ncbi:11103">hepatitis C virus</span>
Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication.
###end article-title 109
###begin article-title 110
###xml 32 49 <span type="species:ncbi:11103">hepatitis C virus</span>
A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication.
###end article-title 110
###begin article-title 111
###xml 0 17 <span type="species:ncbi:11103">Hepatitis C virus</span>
Hepatitis C virus NS5A: Tales of a promiscuous protein.
###end article-title 111
###begin article-title 112
###xml 21 31 <span type="species:ncbi:54290">GB virus C</span>
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Enhanced and resumed GB virus C replication in HIV-1-infected individuals receiving HAART.
###end article-title 112
###begin article-title 113
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
GB Virus C during the natural course of HIV-1 infection: viremia at diagnosis does not predict mortality.
###end article-title 113
###begin article-title 114
###xml 27 32 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
GB Virus C coinfection and HIV-1 disease progression: The Amsterdam cohort study.
###end article-title 114
###begin article-title 115
###xml 54 59 <span type="species:ncbi:9606">Human</span>
Fluorescence-based quantitative methods for detecting Human Immunodeficiency Virus Type 1-induced syncytia.
###end article-title 115
###begin article-title 116
Microneutralization Test for the Determination of Mumps Antibody in Vero Cells.
###end article-title 116
###begin article-title 117
Lentivirus vectors pseudotyped with filoviral envelope glycoproteins transduce airway epithelia from the apical surface independently of folate receptor alpha.
###end article-title 117
###begin p 118
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
###xml 111 116 <span type="species:ncbi:54290?0.912621359223301">GBV-C</span>
###xml 147 150 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 263 266 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Competing Interests: Drs. Xiang and Stapleton hold a patent (United States Patent No. 7,291,723) on the use of GBV-C as a therapeutic modality for HIV, and Drs. Xiang, McLinden and Stapleton have a patent application pending related to the use of NS5A as an anti-HIV therapy.
###end p 118
###begin p 119
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by Merit Review Grants from the Veterans Administration (JX and JTS), and by an NIH RO1 grant (AI-58740, JTS). The funders of this work had no input into the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.
###end p 119

